2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.27 Quintanal-Villalonga

PP01.27 Quintanal-Villalonga - Poster

Pdf Summary

In a study focusing on Diffuse Pleural Mesothelioma (DPM), researchers investigated the potential of targeting TROP-2, a transmembrane protein, as a therapeutic strategy. DPM currently lacks approved therapies beyond first-line options, highlighting the need for novel treatment approaches. The study found that high TROP-2 expression is associated with tumorigenesis and poor outcomes in various cancers, although its specific role in DPM was unclear. By using antibody-drug conjugates (ADCs) to target TROP-2, researchers observed promising results in DPM patient-derived xenograft models. This study provided evidence supporting the potential of TROP-2 as a target for therapy in DPM, paving the way for further clinical investigation. A phase 2 trial is underway to evaluate the efficacy of sacituzumab govitecan (SG) in patients with recurrent or metastatic DPM. The research confirmed the oncogenic effects of TROP-2 in DPM cell lines and its contribution to metastasis in vivo. Pathway analyses revealed that TROP-2 drives oncogenic pathways in DPM, supporting its significance as a therapeutic target. Overall, these findings suggest that targeting TROP-2 with SG shows promise in treating DPM and warrants further exploration in clinical trials.

Keywords

Diffuse Pleural Mesothelioma

TROP-2

transmembrane protein

therapeutic strategy

antibody-drug conjugates

ADCs

patient-derived xenograft models

sacituzumab govitecan

oncogenic effects

metastasis